Last reviewed · How we verify
Placebo (for Selegiline)
Placebo produces no pharmacological effect and serves as an inert control in clinical trials to measure the baseline response independent of active drug treatment.
Placebo produces no pharmacological effect and serves as an inert control in clinical trials to measure the baseline response independent of active drug treatment. Used for Control arm in Phase 3 trial for mood and anxiety disorders (Selegiline comparison).
At a glance
| Generic name | Placebo (for Selegiline) |
|---|---|
| Sponsor | Mood and Anxiety Research, Inc |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inactive substance administered in controlled trials to establish a baseline for comparison against the active investigational drug (in this case, Selegiline). Any therapeutic benefit observed in placebo recipients is attributed to natural disease progression, regression to the mean, or psychological expectation effects. This allows researchers to isolate the true efficacy of Selegiline by comparing outcomes between placebo and active treatment groups.
Approved indications
- Control arm in Phase 3 trial for mood and anxiety disorders (Selegiline comparison)
Common side effects
- Placebo response (symptom improvement without active drug)
Key clinical trials
- Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients (PHASE2)
- Selegiline for Smoking Cessation - 1 (PHASE2)
- Effectiveness of Selegiline in Treating Marijuana Dependent Individuals - 1 (PHASE2)
- Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1 (PHASE3)
- Selegiline Patch for Treatment of Nicotine Dependence (PHASE2)
- Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder (PHASE3)
- Usefulness of Selegiline as an Aid to Quit Smoking - 1 (PHASE2)
- Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (for Selegiline) CI brief — competitive landscape report
- Placebo (for Selegiline) updates RSS · CI watch RSS
- Mood and Anxiety Research, Inc portfolio CI